400 related articles for article (PubMed ID: 16820342)
1. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension.
Watanabe S; Okura T; Kurata M; Irita J; Manabe S; Miyoshi K; Fukuoka T; Gotoh A; Uchida K; Higaki J
Clin Exp Hypertens; 2006 Jul; 28(5):451-61. PubMed ID: 16820342
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension.
Okura T; Watanabe S; Kurata M; Koresawa M; Irita J; Enomoto D; Jotoku M; Miyoshi K; Fukuoka T; Higaki J
Clin Exp Hypertens; 2008 Jul; 30(5):415-22. PubMed ID: 18633763
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
Savoia C; Touyz RM; Volpe M; Schiffrin EL
Hypertension; 2007 Feb; 49(2):341-6. PubMed ID: 17159079
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
[TBL] [Abstract][Full Text] [Related]
5. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
Kucukler N; Kurt IH; Topaloglu C; Gurbuz S; Yalcin F
J Cardiovasc Med (Hagerstown); 2012 Mar; 13(3):181-6. PubMed ID: 22306782
[TBL] [Abstract][Full Text] [Related]
6. Influence of ATII blockers and calcium channel blockers on renal vascular resistance in patients with essential hypertension.
Delić-Brkljacić D; Galesić K; Ivanac G; Manola S; Pintarić H; Stambuk K; Gaćina P; Radeljić V
Coll Antropol; 2009 Dec; 33(4):1129-38. PubMed ID: 20102058
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of intrarenal hemodynamics by Doppler ultrasonography for renoprotective effect of angiotensin receptor blockade.
Ogata C; Kamide K; Suzuki Y; Sasaki O; Kubota Y; Sato H; Takiuchi S; Horio T; Inenaga T; Kawano Y
Clin Nephrol; 2005 Nov; 64(5):352-7. PubMed ID: 16312262
[TBL] [Abstract][Full Text] [Related]
8. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
9. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.
Plum J; Bünten B; Németh R; Grabensee B
J Am Soc Nephrol; 1998 Dec; 9(12):2223-34. PubMed ID: 9848776
[TBL] [Abstract][Full Text] [Related]
10. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients.
Uchida J; Machida Y; Iwai T; Iguchi T; Kamada Y; Naganuma T; Kumada N; Kim T; Kawashima H; Nakatani T
J Nephrol; 2011; 24(4):515-21. PubMed ID: 21240871
[TBL] [Abstract][Full Text] [Related]
11. Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Karalliedde J; Maltese G; Hill B; Viberti G; Gnudi L
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1899-905. PubMed ID: 23929932
[TBL] [Abstract][Full Text] [Related]
12. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients.
Munakata M; Nagasaki A; Nunokawa T; Sakuma T; Kato H; Yoshinaga K; Toyota T
Am J Hypertens; 2004 Nov; 17(11 Pt 1):1050-5. PubMed ID: 15533733
[TBL] [Abstract][Full Text] [Related]
13. Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT).
Yasuda T; Endoh M; Suzuki D; Yoshimura A; Ideura T; Tamura K; Kamata K; Toya Y; Umemura S; Kimura K;
Hypertens Res; 2013 Mar; 36(3):240-6. PubMed ID: 23154591
[TBL] [Abstract][Full Text] [Related]
14. Suppressive effects of valsartan on microalbuminuria and CRP in patients with metabolic syndrome (Val-Mets).
Shishido T; Konta T; Nishiyama S; Miyashita T; Miyamoto T; Takasaki S; Nitobe J; Watanabe T; Takeishi Y; Kubota I
Clin Exp Hypertens; 2011; 33(2):117-23. PubMed ID: 21269062
[TBL] [Abstract][Full Text] [Related]
15. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.
Katayama K; Nomura S; Ishikawa H; Murata T; Koyabu S; Nakano T
Kidney Int; 2006 Jul; 70(1):151-6. PubMed ID: 16710356
[TBL] [Abstract][Full Text] [Related]
16. [The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan].
Zhao C; Wang YY; Xiao ZX; Wang YP; Zhang QY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):428-31. PubMed ID: 17680535
[TBL] [Abstract][Full Text] [Related]
17. Short term effects of valsartan on portal blood flow in cirrhotic patients.
Yalniz M; Demir A; Arslan A; Cihangiroğlu M
Turk J Gastroenterol; 2003 Mar; 14(1):18-25. PubMed ID: 14593533
[TBL] [Abstract][Full Text] [Related]
18. Amlodipine seems to be superior to valsartan in decreasing microalbuminuria in newly diagnosed hypertensive patients: a novel effect to be explained with hyperfiltration?
Ay SA; Cakar M; Karaman M; Balta S; Demirkol S; Unlu M; Kurt O; Altun B; Akhan M; Arslan E; Koc B; Bulucu F
Ren Fail; 2013; 35(3):357-60. PubMed ID: 23297711
[TBL] [Abstract][Full Text] [Related]
19. Intrarenal and carotid hemodynamics in patients with essential hypertension.
Okura T; Watanabe S; Miyoshi K; Fukuoka T; Higaki J
Am J Hypertens; 2004 Mar; 17(3):240-4. PubMed ID: 15001198
[TBL] [Abstract][Full Text] [Related]
20. Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study.
Ohishi M; Takagi T; Ito N; Tatara Y; Hayashi N; Shiota A; Iwamoto Y; Katsuya T; Rakugi H; Ogihara T
Hypertens Res; 2007 Dec; 30(12):1187-92. PubMed ID: 18344623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
